联环药业(600513.SH)公告称，公司间接股东扬州产业投资发展集团有限责任公司的工商变更登记手续 已办理完成，扬州市人民政府国有资产监督管理委员会已将其所持产发集团6.45%的股权无偿划转至江 苏省财政厅。 ...

资金流向方面，今日该股主力资金净流入3172.22万元，其中，特大单净流入3134.53万元，大单资金净 流入37.69万元。近5日主力资金净流出3903.84万元。 10月25日公司发布的三季报数据显示，前三季度公司共实现营业收入20.82亿元，同比增长26.63%，实 现净利润-3506.21万元。（数据宝） 联环药业11月11日交易公开信息 | 买/ | 会员营业部名称 | 买入金额（万 | 卖出金额（万 | | --- | --- | --- | --- | | 卖 | | 元） | 元） | | 买一 | 国泰海通证券股份有限公司总部 | 3460.36 | | | 买二 | 高盛(中国)证券有限责任公司上海浦东新区世纪大道证券 | 2452.01 | | | | 营业部 | | | | 买三 | 国泰海通证券股份有限公司上海长宁区江苏路证券营业部 | 1387.93 | | | 买四 | 中信证券股份有限公司上海分公司 | 1229.36 | | | 买五 | 平安证券股份有限公司北京金融大街证券营业部 | 1198.70 | | | 卖一 | 国泰海通证券股份有限公司总部 | | 2180.84 ...

关于公司原料药产品左炔诺孕酮通过世界卫生组织 证券代码：600513 股票简称：联环药业 公告编号：2025-084 江苏联环药业股份有限公司 预认证现场检查的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏联环药业股份有限公司（以下简称"公司"）于近日收到世界卫生组织 （WHO）通知。世界卫生组织预认证团队对公司原料药产品左炔诺孕酮 （APIMF484,WHOAPI-484）（以下简称"该产品"）的现场检查现已关闭，结果 为符合世界卫生组织良好生产规范（GMP）的标准。现将相关情况公告如下： 一、GMP现场检查相关信息 企业名称：江苏联环药业股份有限公司 生产地址：江苏省扬州市扬州生物健康产业园健康一路 9 号 检查范围：合成区：C7-H5 生产线、C4-H3 生产线；洁净区：C4 厂房 6 号洁 净区 检查时间：2025.03.10—2025.03.13 检查结论：世界卫生组织预认证团队对公司原料药产品左炔诺孕酮 （APIMF484,WHOAPI-484）的现场检查现已关闭，结果为符合世界卫生组织良好 生产规范（ ...

Market Overview - On November 10, the Jiangsu state-owned enterprise reform sector rose by 1.09% compared to the previous trading day, with Xuelang Environment leading the gains [1] - The Shanghai Composite Index closed at 4018.6, up 0.53%, while the Shenzhen Component Index closed at 13427.61, up 0.18% [1] Stock Performance - Xuelang Environment (300385) closed at 6.28, with a gain of 4.49% and a trading volume of 270,400 shares, amounting to a transaction value of 171 million [1] - Jianshi Family (603369) closed at 39.22, up 3.78%, with a trading volume of 168,300 shares and a transaction value of 651 million [1] - Jiangtian Chemical (300927) closed at 28.69, up 3.72%, with a trading volume of 90,700 shares and a transaction value of 257 million [1] - Other notable stocks include Weivi Co. (600300) with a 3.63% increase and a transaction value of 269 million, and Jiangsu Jinzu (600901) with a 3.57% increase and a transaction value of 261 million [1] Capital Flow - The Jiangsu state-owned enterprise reform sector saw a net inflow of 99.64 million from main funds, while retail investors experienced a net outflow of 81.07 million [2] - The main funds showed a significant presence in stocks like Huatai Securities (601688) with a net inflow of 154 million, while retail investors withdrew from stocks like Xuelang Environment and Weivi Co. [3]

Core Points - The company received notification from the World Health Organization (WHO) regarding the successful closure of the on-site inspection for its active pharmaceutical ingredient, Levonorgestrel (APIMF484, WHOAPI-484) [1] - The inspection results indicate that the company's production line complies with WHO Good Manufacturing Practice (GMP) standards, which is beneficial for maintaining stable product quality and production capacity to meet market demand [1] - The successful WHO pre-certification inspection is not expected to have a significant impact on the company's recent performance [1]

Core Viewpoint - The company received notification from the World Health Organization that its raw material drug product, Levonorgestrel, has passed the site inspection, meeting the WHO's good manufacturing practice standards [1] Group 1: Inspection Details - The inspection took place from March 10 to March 13, 2025, covering the synthesis area and part of the cleanroom production lines [1] - The successful inspection is expected to help maintain product quality and production capacity [1] Group 2: Financial Impact - The inspection results are not expected to have a significant impact on the company's recent performance [1] - The drug master file review has not been closed, indicating uncertainty regarding future procurement [1]

Core Viewpoint - The company, Lianhuan Pharmaceutical, has successfully passed the World Health Organization's (WHO) pre-certification inspection for its active pharmaceutical ingredient, Levonorgestrel, indicating compliance with Good Manufacturing Practice (GMP) standards [1] Group 1: Company Performance - The successful completion of the WHO inspection demonstrates that the company's production line meets GMP requirements, which is crucial for maintaining stable product quality [1] - The inspection results are expected to support the company's ability to sustain stable production capacity to meet market demand for related pharmaceuticals [1] Group 2: Market Impact - The passing of the WHO pre-certification inspection is not anticipated to have a significant impact on the company's recent performance [1]

Core Viewpoint - The announcement details a change in the equity structure of Jiangsu Lianhuan Pharmaceutical Co., Ltd. (hereinafter referred to as "Lianhuan Pharmaceutical") due to the transfer of state-owned shares from the controlling shareholder, Jiangsu Lianhuan Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Lianhuan Group"), to the Jiangsu Provincial Department of Finance, which will not affect the company's operational control or shareholding structure [2][3]. Summary of Key Points 1. Change in Controlling Shareholder's Equity Structure - The Jiangsu Provincial State-owned Assets Supervision and Administration Commission (hereinafter referred to as "Yangzhou SASAC") transferred 10% of its shares in Lianhuan Group and 6.45% of its shares in Yangzhou Industrial Investment Development Group Co., Ltd. (hereinafter referred to as "Investment Group") to the Jiangsu Provincial Department of Finance without compensation [2][4]. - This transfer will not change the number of shares or the proportion of shares held by Lianhuan Group in Lianhuan Pharmaceutical [2][3]. 2. Regulatory Compliance - According to the relevant provisions of the "Measures for the Administration of Takeovers of Listed Companies," this transfer does not trigger a mandatory tender offer [3][4]. 3. Impact on Company Operations - The equity structure change will not alter the controlling shareholder or actual controller of the company, and it will not have a substantial impact on the company's daily operations and production activities [3][9]. - After the transfer, the Jiangsu Provincial Department of Finance will indirectly hold 4.968% of Lianhuan Pharmaceutical's shares through Lianhuan Group and Investment Group [5][7]. 4. Future Developments - As of the announcement date, the relevant industrial and commercial change registration procedures for Lianhuan Group have been completed, while those for Investment Group are still in progress [9].

证券代码：600513 证券简称：联环药业 公告编号：2025—083 江苏联环药业股份有限公司 关于控股股东股权结构变动的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●江苏联环药业股份有限公司（以下简称"联环药业"或"公司"）控股股 东江苏联环药业集团有限公司（以下简称"联环集团"）股权结构变动系公司实 际控制人扬州市人民政府国有资产监督管理委员会（以下简称"扬州市国资委"） 将其持有的联环集团10%的股权、扬州产业投资发展集团有限责任公司（以下简 称"产发集团"）6.45%的股权无偿划转至江苏省财政厅（以下简称"本次国有 股权无偿划转"），本次国有股权无偿划转不会导致联环集团持有公司股份数量 及持股比例发生变化。 ●根据《上市公司收购管理办法》的相关规定，本次国有股权无偿划转不触 及要约收购。 ●本次公司控股股东股权结构变动不会导致公司控股股东及实际控制人发 生变化，不会对公司日常经营和生产活动产生实质性影响。 一、控股股东股权结构变动基本情况 62.00% 100.00% 38.00% 3 ...

Core Viewpoint - The announcement indicates a transfer of equity stakes in Lianhuan Pharmaceutical, with the Jiangsu Provincial Finance Department increasing its indirect shareholding by 4.968% following the transfer of shares from the Yangzhou State-owned Assets Supervision and Administration Commission [1] Group 1 - The Yangzhou State-owned Assets Supervision and Administration Commission transferred 10% of its shares in Lianhuan Group and 6.45% of its shares in Chanfa Group to the Jiangsu Provincial Finance Department without compensation [1] - After the transfer, the Jiangsu Provincial Finance Department's indirect shareholding in the company increased by 4.968%, while the Yangzhou State-owned Assets Supervision and Administration Commission's indirect shareholding decreased by the same percentage [1] - Lianhuan Group continues to hold 39.90% of the company's shares directly, and the controlling shareholder and actual controller remain unchanged, ensuring no impact on daily operations [1]